Wed, Mar 4, 2015, 3:58 AM EST - U.S. Markets open in 5 hrs 32 mins

Recent

% | $
Quotes you view appear here for quick access.

InVivo Therapeutics Holdings Corp. Message Board

  • mp.indiana mp.indiana Sep 2, 2013 9:32 PM Flag

    NVIV Part 7

     

    Part 7
    Let’s say you are the CEO of a biotech or pharmaceutical company and you’re interested in NVIV for the hydrogel and/or other products. Let us further assume that while you realize there’s a humanitarian benefit in the scaffolding, it’s not your primary interest. Your main interest is the hydrogel. With a market value worth tens of billions, the hydrogel and the other products make NVIV an extremely desirable purchase candidate. The only problem is you can’t buy it, at least not at a reasonable price, not while Frank’s in charge. Your only solution is to wait and see how things evolve. Well last week things evolved actually quite a bit.

    Frank’s now no longer in control. Yes, he still owns 30% of the company, but he is no longer calling the shots. The company stock has taken a horrific beating (I am by no means suggesting anyone had anything to do with this stock price collapse but the Short Sellers) as such, longtime holders of the stock would love to sell their positions for a reasonable price. For an opportunistic pharmaceutical or biotech CEO this would seem like an ideal situation.

    Excluding the monkey studies for now, what are the products worth? It takes somewhere between $2-$5 billion to bring a new drug to market in the US. Ironically, the level of improvement that these drugs purport to show is sometimes less than 5 to 10% efficacy. I’ve talked to physicians and surgeons regarding the hydrogel and what effect it would have on their practices if it works as proposed. Their answers are always the same. The results would be staggering. It would have immediate and life-changing effects on the treatments for chronic pain. This is the kind of product that can have huge ramifications for the company that owns it.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
NVIV
3.04+0.02(+0.66%)Mar 3 3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.